CASTLE BIOSCIENCES INC
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Castle Biosciences
Services-Medical Laboratories, SIC 8071
Castle Biosciences is a molecular diagnostics company that develops and provides diagnostic and prognostic tests for dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. Its commercial tests include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, and DecisionDx-UM. These tests analyze patient biology using multi-analyte assays, proprietary algorithms, and gene expression profiling to provide clinically actionable data that assists in diagnosing diseases, predicting recurrence or metastasis, and guiding treatment pathways. The company’s customers are healthcare providers and clinicians who order tests to guide patient management.
The company operates clinical laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, and is authorized to provide testing services across all fifty United States. Its direct sales and commercial marketing efforts focus primarily on healthcare providers in the United States. Castle Biosciences has delivered more than 419,000 clinical patient test reports since inception and maintains patent rights across domestic and foreign jurisdictions. The provided text does not mention the location of its corporate headquarters.
Summary of the business section of Castle Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CASTLE BIOSCIENCES INC
- Founded
- 2008
- Headquarters
- Friendswood, TX
- Address
- 1500 W. Parkwood Ave., Suite 400 77546
- Phone
- (866) 788-9007
- Employees
- 883, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Houston, TX
Stock & identifiers
- Ticker
- CSTL
- Exchange
- Nasdaq
- IPO date
- Jul 26, 2019
- Shares outstanding
- 31M, Jul 23, 2026
- Public float
- $576.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1447362
- CUSIP
- 14843C105
- ISIN
- US14843C1053
- LEI
- 2549007M2Q4HLR1XD252
- EIN
- 77-0701774
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Derek J. Maetzold | Pres. & Chief Exec. Officer, Director | 181,715 |
| Tobin W. Juvenal | Chief Commercial Officer | 60,814 |
| Kristen M. Oelschlager | Chief Operating Officer | 90,157 |
| Frank Stokes | Chief Financial Officer | 35,177 |
| Ellen Goldberg | Director | 40,921 |
| Kim Caple | Director | 36,121 |
| G. Bradley Cole | Director | 32,976 |
| Rodney Cotton | Director | 32,998 |
| Daniel Bradbury | Director | 35,631 |
| Miles Harrison | Director | 35,631 |
| Tiffany Olson | Director | 39,573 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Maetzold | $6.79M | $13.17M | $2.38M | $58 | $125 |
| FY2024 Mr. Maetzold | $6.94M | $9.97M | $2.40M | $40 | $93 |
| FY2023 Mr. Maetzold | $1.61M | $779.82K | $845.95K | $32 | $94 |
| FY2022 Mr. Maetzold | $7.55M | $3.08M | $2.67M | $35 | $90 |
| FY2021 Mr. Maetzold | $6.52M | $2.13M | $2.81M | $64 | $100 |
| FY2020 Mr. Maetzold | $5.34M | $13.31M | $1.95M | $195 | $125 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 883 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 14, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 6, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 26, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 15, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |